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ABSTRACT
MicroRNA-34a (miR-34a) plays an essential role against tumorigenesis and 
progression of cancer metastasis. Here, we analyzed the expression, targets and 
functional effects of miR-34a on epithelial to mesenchymal transition-inducing 
transcription factors (EMT-TFs), such as TWIST1, SLUG and ZEB1/2, and an EMT-
inducing protein NOTCH1 in breast cancer (BC) cell migration and invasion and 
its correlation with tumorigenesis and clinical outcomes. Expression of miR-34a 
is downregulated in human metastatic breast cancers (MBC) compared to normal 
breast tissues and is negatively correlated with clinicopathological features of MBC 
patients. Ectopic expression of miR-34a in MBC cell-line BT-549 significantly inhibits 
cell migration and invasion, but exhibits no clear effect on BC cell growth. We found 
that miR-34a is able to inactivate EMT signaling pathway with mediatory of NOTCH1, 
TWIST1, and ZEB1 upon 3′-UTR activity in MBC cell lines, but has no inhibitory 
effects on SLUG and ZEB2. Furthermore, we investigated the synergistic effects of 
Thymoquinone (TQ) and miR-34a together on the expression of EMT-associated 
proteins. Results showed that co-delivery of miR-34a and TQ is able to inactivate 
EMT signaling pathway by directly targeting TWIST1 and ZEB1 in BT-549 cell line, 
indicating that they might be a promising therapeutic combination against breast 
cancer metastasis. Epigenetic inactivation of the EMT-TFs/miR-34a pathway can 
potentially alter the equilibrium of these regulations, facilitating EMT and metastasis 
in BC. Altogether, our findings suggest that miR-34a alone could serve as a potential 
therapeutic agent for MBC, and together with TQ, their therapeutic potential is 
synergistically enhanced.




From historical to contemporary science, metastatic 
breast cancers (MBC) have become one of the deadliest 
female malignancies worldwide with >41,000 deaths 
per year [1, 2]. Despite significant progresses in clinical 
treatment strategies of MBC, the 5-year survival rate 
after curative resection is reported to be only ~24% [3]. 
Chemotherapy, radiotherapy and molecularly targeted 
therapy are the main components of MBC therapy [4]. The 
clinically heterogeneous nature of MBC relatively arises 
from its biological and genetic heterogeneity. Therefore, 
a better understanding of the genetic and molecular 
characteristics of MBC is warranted to decrease mortality 
and improve patient's quality of life [5]. A variety of 
genetic and epigenetic abnormalities characterizes the 
development of the metastatic process, where epithelial to 
mesenchymal transition (EMT) plays a vital, supportive 
role for local invasion, migration, growth, and drug 
resistance of breast cancer (BC) cells [6, 7].
EMT is characterized by the loss of epithelial cell 
polarity and tight cell-cell junction, such as E-cadherin and 
β-catenin, leading to the enhancement of the migratory and 
invasive attributes and the appearance of mesenchymal 
biomarkers, such as N-cadherin and vimentin [8, 9]. EMT 
is modulated by different extracellular signals and several 
activating transcription factors, such as members of the 
SNAIL, zinc-finger E-box-binding (ZEB) and basic helix-
loo-helix (bHLH) families, including zinc finger protein 
SNAI2 (SLUG), Twist-related protein 1 (TWIST1), 
ZEB1 and ZEB2, which are master coordinators of EMT 
and the metastatic program [10–13]. The EMT-inducing 
transcription factors (EMT-TFs) induce EMT responses 
during tumor metastases by binding to the E-box 
sequences in the proximal promoter region of the repress 
epithelial genes and recruiting another post-translational 
modifications bio-machines [9, 10, 14]. In the early stages 
of MBC, EMT-TFs, like TWIST1, ZEB1/2, and SLUG, 
repress E-cadherin and β-catenin expression; promote 
EMT, cell motility and invasiveness; and permit the 
intravasation of tumor cells [15–18].
Recently, microRNA-34a (miR-34a) was identified 
as a novel class of tumor-suppressive miRNAs that is 
downregulated in several human cancers, including breast, 
lung, and liver; re-introduction of miR-34a mimics the 
inhibition of cancer cell growth and metastasis [19–21]. 
miR-34a resides on the chromosomal locus 1p36.23 and 
is involved directly and indirectly with many different 
oncogenic processes, including growth, survival, 
differentiation, proliferations, migration, invasion, and 
immune responses [20]. Accordingly, overexpression 
of miR-34a acts as a mediator of tumor suppression 
by transcriptionally regulating TP53, NOTCH, and 
transforming growth factor beta (TGF-β) signaling 
pathways [14, 20, 22–25]. So far, it is unclear whether 
miR-34a epigenetically silences EMT by binding to 
EMT-TFs in BC. Previous studies have shown that 
downregulation of TWIST1, SNAIL1, and SLUG has a 
key role in aggregating MBC treatment and increasing 
EMT-TFs levels correlated with poor prognosis in a MBC 
[11, 14, 26].
Evidence implies that miR-34a is a promising 
non-invasive biomolecular tool for gene regulation in 
the metastatic process by coordinating TP53, NOTCH1, 
and TGF-β-pathways [27–29]. Since different cancer cell 
types display differences in the expression and relevance 
of EMT regulators [30–32], current attention is focused on 
systematically analyzing EMT-TFs’ regulatory mechanism 
and EMT-TFs/miR-34a feedback loop, like the role of 
TWIST1, SLUG, ZEB1/2 and SNAIL1 in promoting BC 
migration, invasion and metastasis.
We aimed to investigate the role of miR-34a in 
human breast tumors with a focus on MBC. Here, we 
found that miR-34a potentially inhibits TFs, like TWIST1 
and ZEB1, and EMT-associated protein NOTCH1 
expression upon the 3’-untranslated region (3’-UTR) in 
BC cells. Transient transfection of miR-34a significantly 
inhibits cell proliferation, cell migrations, cell survival 
and cell invasion of BC cell lines by targeting NOTCH1, 
ZEB1, and TWIST1. We have consequently revealed that 
miR-34a is downregulated in MBC tissues and suppresses 
cancer metastasis by affecting several malignancy 
endpoints.
RESULTS
MicroRNA-34a expression in human BC cell 
lines and tissues
Previous investigational screenings for miR-34a 
expressions in different tissues and cancer cell types found 
that the expression of miR-34a is variable in BC [30–32].
Therefore, we first measured the level of mature miR-34a 
in our collected MBC tissues and human BC cell lines 
using quantitative reverse transcriptase-PCR (qRT-PCR). 
Interestingly, the average level of miR-34a expression was 
consistently and significantly lower in tissues of MBC (n 
= 33) than that of normal breast samples (n = 15) (Figure 
1A). In addition, miR-34a levels were significantly lower 
in some MBC cell lines in comparison to non-metastatic 
BC cell line MCF-7 (Figure 1B). There was no expression 
of the miR-34a in the MDA-MB-435 BC cells. The above 
data showed that miR-34a is significantly downregulated 
in MBC tissues, suggesting that the downregulation of 
miR-34a most likely affects the progression of MBC.
MicroRNA-34a expression correlates to 
clinicopathological features
The demographic and clinical characteristics of the 
48 subjects were showed in Table 1. The mean ages of 
these patients were 46.34 ± 9.71 (age range, 26-67 years). 
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There was no statistically significant difference between 
the groups in terms of age and number. The relative 
expression of miR-34a in MBC tissues was significantly 
related to certain clinicopathological features, like 
progesterone receptor and Ki-67 proliferation marker 
status. Furthermore, miR-34a expression levels were 
inversely correlated with Ki-67 (r = −0.23, P = 0.002; 
Figure 1C). Figure 1D presents a positive correlation 
between the miR-34a expression level ratios and PR. 
However, clinicopathological features, such as human 
epidermal growth factor receptor-2, estrogens receptor, 
and TP53, did not exhibit a significant association with 
miR-34a expression (Supplementary Figures 1A-1C). 
In general, a significant correlation between miR-34a 
expression and clinicopathological features of MBC 
patients was observed. Although there is no statistical 
significance observed currently, further research might 
exhibit a significant correlation between miR-34a 
expression level and tumor size (p value is 0.08) as well 
as histological grade (p value is 0.075) if we increase the 
sample size.
MicroRNA-34a inactivates the EMT-TFs 
signaling in BC cell lines
The qRT-PCR and Western blot analysis were 
conducted to investigate whether miR-34a expression 
could remarkably affect the EMT-TFs SNAIL1, SLUG, 
Figure 1: Expression of miR-34a in BC cell lines and BC specimens. A. The expression levels of miR-34a in normal breast 
significantly decreased in human cancer tissues that measured by TaqMan® MicroRNA assays kit. B. Total RNA was prepared from 
the cell lysates and expression of miR-34a was quantified by TaqMan MicroRNA Assays. The expressions of miR-34a was normalized 
against the expression level of U6 snRNA. The expression levels T-47D, BT-549, MDA-MB-231, and MDA-MB-435 were expressed as 
relative to the miR-34a expression level of MCF-7 cells, non-metastatic BC cell lines (mean±SD). Inverse relationship between levels of 
miR-34a in 48 human breast specimens with Ki67 C. PR expression D. The diamond indicates human BC specimens (n = 33), and circles 
represent paired adjacent normal tissue (n = 15). Data were analyzed by Spearman's rank correlation coefficient. In general, it was observed 
significant correlation between the miR-34a expression levels and some clinicopathological features of MBC patients. Data presented is a 
representative of three different experiments. (NM, No measured value; * P<0.05).
Oncotarget21365www.impactjournals.com/oncotarget





miR-34a+ (≥0.74) miR-34a- (<0.74)
Subjects (%) 17 (35.4) 31 (64.6) 0.001
Age (yrs.)
 < mean (27) 10 (20.8) 17 (35.4)
0.517
 ≥ mean (21) 7 (14.6) 14 (29.2)
Tumor histology
 Ductal (30) 3 (9.1) 27 (80.1)
0.238
 Lobular (3) 1 (3.0) 2 (6.1)
Tumor Size
 ≤ 3 cm (4) 2 (6.1) 2 (6.1)
0.08 3-9 cm (24) 2 (6.1) 22 (66.6)
 ≥ 9 cm (5) 0 (0) 5 (15.2)
Diagnosis stage (TNM)
 Stage II (15) 0 (0) 15 (45.5)
0.075
 ≥ Stage III (18) 4 (12.1) 14 (42.4)
Node status
 Negative (26) 3 (8.6) 23 (65.7)
0.162
 Positive (9) 3 (8.6) 6 (17.1)
Neoadjuvant therapy (%)
 Yes (12) 3 (9.4) 9 (28.1)
0.399
 No (20) 3 (9.4) 17 (53.1)
Chemotherapy
 Yes (14) 3 (9.4) 11 (34.4)
0.541
 No (18) 3 (9.4) 15 (46.9)
PR
 Negative (22) 6 (12.5) 16 (33.3)
0.02
 Positive (26) 11 (22.9) 15 (31.2)
ER
 Negative (18) 4 (8.3) 14 (29.2)
0.121
 Positive (30) 13 (27.1) 17 (35.4)
P53
 Negative (34) 13 (32.5) 21 (52.5)
0.60
 Positive (6) 2 (5.0%) 4 (10.0)
Ki67
 ≤ 30 (27) 14 (29.2) 13 (27.1)
0.03
 > 30 (21) 3 (6.2) 18 (37.5)
Her2/neu
 Low/weak (27) 10 (20.8) 17 (35.4)
0.517
 Moderate/strong (21) 7 (14.6) 14 (29.2)
Abbreviations: miR-34a, MicroRNAs-34a; TNM, TNM classification of malignant tumors; ER, estrogens receptor; PR, 
progesterone receptor; HER2, human epidermal growth factor receptor-2.
Data are presented as a number for all others. %, percent of total samples.
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TWIST1, ZEB1 and ZEB2, and NOTCH1 expression 
levels. As shown in Figure 2A, the miR-34a expression 
in BT-549 cells transfected with miR-34a mimic was 
significantly increased. Upon overexpression, miR-
34a reduced NOTCH1, TWIST1, and ZEB1 levels, 
although it expressed a less significant reduction in their 
corresponding protein levels (P > 0.05; Figures 2B-2C), 
indicating both transcriptional and post-transcriptional 
regulations. However, overexpression of miR-34a did not 
substantially affect SLUG, ZEB2 expression (P ≥ 0.05; 
Figure 2: Ectopic expression of miR-34a inhibits the cell migration and invasion in BT-549 BC cells. A. The BT-549 cells 
were transfected with plasmid pre-miR-34a and pre-miR-34a-controls as indicated. The miR-34a expression which measured by stem-
loop qRT-PCR in transfected cells was significantly increased. B. The relative expression of EMT-TFs in BT-549 cells transfected with 
miR-34a mimic were analyzed by qRT-PCR. C. Cells were treated the same as above and protein lysis were further analyzed by Western 
blot assay for the protein expression of EMT-TFs. The over-expressed miR-34a cells reduced NOTCH1, TWIST1, and ZEB1 levels. 
Nevertheless, the SLUG and ZEB2 levels are no change. D. miR-34a dependently inhibited, migration and invasive characteristics of BT-
549 cells. However, no clear effect on cancer cell growth. All data were showed with mean ± SD. Similar results were obtained from three 
independent experiments. The qRT-PCR results normalized to 18S RNA (18S) or U6 snRNA (U6). In Western blot, the β-actin (ACTIN) 
as internal controls. (* P<0.05).
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Figures 2B-2C) and SNAIL1 expression (data not shown). 
Consistently, after the inhibition of miR-34a, TWIST1, 
NOTCH1 and ZEB1 protein levels were significantly 
increased. (Figure 2C). All these results suggested that 
miR-34a is able to inactivate the EMT signaling pathway 
with mediation of NOTCH1, TWIST1 and ZEB1 in MBC 
cell lines.
MicroRNA-34a inhibits migrations and invasion 
in BC cells in vitro
To investigate miR-34a’s effects on BC cell 
growth, migration, and invasion, pre-miR-34a for the 
overexpression of precursor miR-34a (pre-miR-34a), or 
anti-miR-34a for the overexpression or inhibition of miR-
34a, were transiently transfected into the MBC cell lines, 
BT-549 (Figure 2D) and MDA-MB-435 (Supplementary 
Figure 2), respectively. Our results clearly showed that 
miR-34a’s expression did not significantly inhibit cell 
proliferation in BT-549 cells. Pre-miR-34a restoration 
inhibits cell migration and invasion in comparison to 
the pre-controls. Up-regulated miR-34a contributed to a 
significant down-regulation of cell migration and invasion. 
Strikingly, the inhibited-miR-34a in BT-549 BC cells 
showed more significant migrations and invasions after 
12 h of cell culture. Here, we did not observe significant 
changes in cell migration in MDA-MB-435 cell lines with 
anti-miR-34a overexpression (Supplementary Figure 2); 
thus, we concluded that miR-34a functions are dependent on 
MBC cell line types. Therefore, miR-34a suppresses several 
malignancy parameters in human breast tumor cells, but has 
no obvious effects on cancer cell growth.
Evaluation of EMT status and miR-34a in 
BC cell lines
Although previous studies have demonstrated that 
EMT-TFs played a fundamental role in the initiation, 
aggregation, progression, and metastasis of BC by 
inducing the activation of NOTCH1, TP53, and TGF-β 
cascade [10, 13, 33], EMT-TFs’ expression patterns, in 
comparison to miR-34a, have not been well characterized 
in human BC. To assess whether EMT-TFs and NOTCH1 
are important mediators of metastatic potential in BC 
cells, we first evaluated NOTCH1, TWIST1, SLUG, and 
ZEB1/2 expression in a panel of established metastatic and 
non-metastatic BC cell lines (Figure 3). NOTCH1, SLUG, 
TWIST1, and ZEB1/2 expression levels, in contrast to 
miR-34a, were verified in BC cell lines, which confirmed 
that NOTCH1 and EMT-TFs partially inhibit miR-34a 
expression in cells (Figures 3A-3E). Altogether, these data 
suggested that NOTCH1 (Figure 3A), TWIST1 (Figure 
3C), and ZEB1 (Figure 3D) are reverse correlated with 
miR-34a in the both MBC and BC cell lines (especially 
BT-549 and MDA-MB-435 cell lines) (P≤0.001). 
However, the relative expression of the SLUG and ZEB2 
Figure 3: EMT-TFs demonstrate high expression levels in MBC cell lines in front of miR-34a expression. Relative 
expression levels of NOTCH1 A., SLUG B., TWIST1 C., and ZEB1 D. and ZEB2 E. were detected in non-metastatic BC cell lines (MCF7 
and T47D), and MBC cell lines (MDA-MB-231, MDA-MB-435 and BT-549), in comparison to relative expression levels of miR-34a using 
qRT-PCR. F. EMT-TFs expression level was detected in MBC cell lines by western blot. Totally, EMT-TFs were overexpressed in invasive 
BC cell lines. Similar results were obtained from three independent experiments. Horizontal bars show with mean±SD. The Tubulin (TUB) 
in western blot assay, and 18S or U6 in qRT-PCR as controls. (* P<0.05 and ** P<0.001 versus MCF-7 group).
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and miR-34a expression was not significantly co-related 
in BC cell lines (Figures 3B and 3E, respectively). In 
addition, the EMT-TFs protein expression was higher 
in both MBC cell lines, MDA-MB-435 and BT549 in 
comparison to non-metastatic BC cell lines (Figure 3F). 
In considering both gene and protein levels, TWIST1, 
SLUG, and ZEB1 expressions were higher compared to 
the lower expression of miR-34a. These results suggested 
that the expression of EMT-TFs positively correlates with 
the metastatic potential of BC cell lines.
EMT-TFs overexpression in malignant 
progression of BC tumors
To emphasize the role of EMT-TFs in promoting 
tumor metastasis, the expressions for NOTCH1, SLUG, 
TWIST1, and ZEB1/2 were examined by qRT-PCR 
from BC and their normal adjacent tissues. As the Figure 
4 showed, the expressions of NOTCH1, SLUG, and 
ZEB1/2 were significantly increased in tissue samples 
compared to the matched-control group (Figure 4A). 
These results demonstrated a significant increase of EMT-
TFs in cancer tissues. For each case of 33 patients, an 
index of all EMT-TFs and NOTCH1 expression of the 
MBC tissue (qRT-PCR score) was subtracted by that of 
normal tissue, and the resultant values (malignant-NAT) 
from all 33 cases were presented in Figure 4B. Of the 
33 cases examined, 19 (57.58%) showed significantly 
higher expression of EMT-TFs in the cancerous tissues 
in comparison to the corresponding adjacent normal 
tissues; while another 7 (21.21%) showed similar levels 
of expression in both tissues; only 7 (21.21%) displayed a 
reverse expression pattern, in which EMT-TFs expression 
was lower in the cancer tissues than that of normal groups. 
So, EMT-TFs are differentially expressed in malignant BC 
tissue compared to the normal tissue.
We then analyzed the association between 
survival time and NOTCH1, TWIST1, SLUG, and 
ZEB1/2 with an online tool [34] to further extend 
the clinicopathologically-relevant context, with the 
exclusion of systemic treatment, endocrine therapy, and 
chemotherapy. The results revealed that higher ZEB1 
expression was considerably associated with a worse 
overall survival (OS, HR = 0.55, P = 0.0083), worse 
relapse free survival (RFS, HR = 0.64, P = 0.001), 
post progression survival (PPS, HR = 0.64, P = 0.062), 
and distant metastasis free survival (DMFS, HR = 0.6, 
P = 0.0003) of BC patients (Figure 4C). There was no 
significant difference between SLUG, NOTCH1, ZEB2, 
and TWIST1 in BC patients (Table 2). These data 
indicated that ZEB1 could be used as the most important 
potential predictor of survival in the BC patients.
In considering both tumor and normal samples, miR-
34a was inversely correlated with NOTCH1 (r = −0.563, P 
= 0.001; Figure 5A), SLUG (r = −0.374, P = 0.009; Figure 
5B), ZEB1 (r = −0.505, P = 0.001; Figure 5C), and ZEB2 
(r = −0.317, P = 0.028; Figure 5D) expressions. We found 
that TWIST1 ratios were not significantly correlated with 
the frequencies of miR-34a expression (r = −0.093, P = 
0.532; data not shown). Therefore, we proposed that EMT-
TFs over-expression might suppress miR-34a expression 
of BC.
MicroRNA-34A inhibits BC progression by 
targeting TWIST1, NOTCH1, and ZEB1
We next explored whether miR-34a is able to 
directly target NOTCH1, TWIST1 and ZEB1 gene 
expression at the post-transcriptional level by regulating 
the activity of mRNA (Figure 6). First, prediction on-
line databases, like miR base databases, identified that 
NOTCH1, TWIST1 and ZEB1 were potential downstream 
targets of miR-34a through their interactions in the 
3’-UTR region (Figure 6A). Thus, luciferase reporter 
assays carried out by co-transfection of different amount 
of pre-miR-34a (0, 10, 30, and 90 ng each well) along 
with NOTCH1, TWIST1 and ZEB1 wild-type 3’-UTR 
reporter genes respectively in BT-549 cells contributed 
to significant reductions in luciferase activity (Figures 
6B-6D). Luciferase activities are significantly reduced in 
a dose dependent manner in all NOTCH1, TWIST1 and 
ZEB1 reporter genes. However, co-transfection of miR-
34a, along with the NOTCH1, TWIST1, and ZEB1-mut 
3’-UTR or control reporter genes, did not show significant 
effects on the luciferase activity. These results suggested 
that miR-34a directly targets multiple genes of NOTCH1, 
TWIST1, and ZEB1 in vitro.
Co-delivery of miR-34A and Thymoquinone 
inhibits BC metastasis by regulating EMT-TFs
Our previous investigation reported that 
Thymoquinone (TQ), small molecular component of 
Nigella sativa, could be used as an inhibitor of cancer 
growth and metastasis [35]. The epigenetic modulation 
of the EMT promoter is associated with TWIST1 and 
cadherins down-regulation and metastasis by TQ treatment 
in BC cells [35]. With this background, we investigated the 
synergistic effects of TQ and miR-34a on the expression of 
EMT-associated proteins. Cancer cells were treated with 
TQ, pre-miRNAs vector, or both. Both proteins and gene 
analysis showed that TQ+miR-34a significantly inhibited 
the mRNA level expression of NOTCH1 (P = 0.073; 
Figure 7A) TWIST1 (P = 0.062; Figure 7B) and ZEB1 
(P = 0.005; Figure 7C) in the BT-549 cell line. However, 
no significant changes in NOTCH1 and ZEB1 expression 
were observed in the TQ treated groups (Figures 7A and 
7C, respectively). Interestingly, the protein levels of ZEB2 
and SLUG were expressed minimally or completely 
unexpressed in three groups in comparison to the control. 
In addition, some extent of reduction in ZEB2 was also 
observed, by TQ through either treatment or miR-34a 
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Figure 4: EMT-TFs are frequently upregulated in BC tissues. A. SLUG, TWIST1 ZEB1/2 and NOTCH1 expression level 
were detected in MBC tissues and matched with the corresponding paired adjacent normal tissue through qRT-PCR. B. EMT-TFs are 
differentially expressed in primary malignant BC tissue compared with the corresponding paired adjacent normal tissue. For each case of 
the 33 patients, index of all EMT-TFs (SLUG, TWIST1, and ZEB1/2) and NOTCH1, expression (qRT-PCR score) of the primary tissue 
was subtracted by that of the corresponding paired adjacent normal tissue, and the resultant values (Malignant-NAT) from all 33 cases 
were used for plotting. The relative of EMT-TFs expression level between primary cancer and paired adjacent tissue of each case were 
represented as a dot. EMT-TFs are considered to be significantly upregulated, similar or negative in primary tissue when compared with 
the corresponding paired adjacent tissue only if the calculated index is >0 (circular dots), 0 (square dot), <0 (triangular dots), respectively. 
C. Kaplan-Meier survival analysis for the relationship between survival time and ZEB1 signature in BC was performed by using the online 
tool (http://kmplot.com/analysis/). All data were showed with mean ± SD. Data presented is a representative of three different experiments. 
The qRT-PCR results were normalized to18S. RFS, relapse free survival; OS, overall survival; DMFS, distant metastasis free survival; PPS, 
post progression survival.
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Table 2: Kaplan-Meier survival analysis for the relationship between survival time and NOTCH1, TWIST1, SLUG, 
and ZEB2 signature in breast cancer
EMT-TFs RFS OS DMSF PPS
TWIST1 0.16 0.19 0.043 0.3
SLUG 0.14 0.18 0.34 0.26
ZEB2 0.05 0.092 0.039 0.11
NOTCH1 0.096 0.14 0.32 0.18
Abbreviations: EMT-TFs, EMT-inducing transcription factors; ZEB1&2, Homo sapiens zinc finger E-box binding 
homeobox 1 and 2; NOTCH1, Notch homolog 1, translocation-associated; SLUG, Zinc finger protein; PPS, post 
progression survival; LSD, least significant difference; RFS, relapse free survival; OS, overall survival; DMFS, distant 
metastasis free survival.
Figure 5: Correlations between relative expression levels of NOTCH1 A., SLUG B., ZEB1 C., and ZEB2 D. with 
miR-34a expression level. Data indicate significantly negative associations in EMT-TFs and miR-34a expressions in MBC patients. 
The diamond indicates human BC specimens (n = 33), and circles represent paired adjacent normal tissue (n = 15). Data were analyzed by 
Spearman's rank correlation coefficient.
Oncotarget21371www.impactjournals.com/oncotarget
overexpression (Supplementary Figure 3). Thus, the 
obtained data proposes that co-delivery of TQ and miR-
34a could produce synergistic effects on tumor growth and 
migrations.
DISCUSSION
The experimental investigation of this study 
identified a novel regulatory mechanism of EMT-TFs 
using miR-34a. Our results indicated that miR-34a 
inhibits TWIST1, ZEB1, and NOTCH1 expression 
upon their 3′-UTR activity in BC cells and reduces the 
metastatic and invasive features of MBC effectively. We 
also revealed that miR-34a expression is down-regulated 
in MBC tissues compared to normal tissues. Moreover, 
we found a significant inverse correlation between miR-
34a expression and EMT-TFs expression. The forced 
miR-34a expression in MBC cell line BT-549 powerfully 
inhibits cell migrations and invasion. Importantly, miR-
34a does not have any inhibitory effects on SLUG and 
ZEB2 in BC cells we investigated. We therefore presented 
the first comprehensive report of epigenetic inactivation 
of the EMT-TFs/miR-34a pathway in human BC that can 
potentially alter the stability of these regulations in EMT 
Figure 6: TWIST1, NOTCH1 and ZEB1 are direct targets of miR-34a. A. miR-34a binding sequences at the 3’-UTR of 
NOTCH1, TWIST1 and ZEB1. Mutation was generated in the NOTCH1, and ZEB1 3’UTR sequence in the complementary site for the 
seed region of miR-34a. BT-549 cells were transfected with either the wild-type or mutant NOTCH1 B., TWIST1 C., ZEB1 D. -3’UTR 
luciferase reporter genes, together with different concentrations of miR-34a mimic or controls (0, 10, 30, and 90 ng). The relative luciferase 
values were measured and normalized by luciferase reporter assay after 48 h. NOTCH1, TWIST1, and ZEB1 expression were directly 
down-regulated by miR-34a. All data were showed with mean ± SD. Similar results were obtained from three independent experiments. 
(* P<0.05 and ** P<0.001 versus 0 ng treated group).
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and mesenchymal state, consequently contributing to 
metastasis.
The underlying mechanisms governing MBC 
remained largely undefined, with few studies proposing 
the inhibitions of EMT-TFs/miR-34a feedback loop as a 
model for the dissemination process. Several signaling 
pathways, such as NOTCH1, TGF-β-SMAD, and Wnt/β-
catenin, initiate the reprogramming of gene expression and 
transcriptional changes during EMT [10, 13, 33]. These 
signaling pathways, along with activating secondary 
pathways, like PI3K–AKT, RAS/MAPK, p38 MAPK and 
JUN N-terminal kinase, regulate the pathogenesis and 
progression of tumor as they control cell proliferation, 
migrations, differentiation, apoptosis, and angiogenesis 
[36, 37] (Figure 8). Dysregulation of these signaling 
pathways and aberrant activations of target genes in the 
EMT-inducing signaling pathways contribute to MBC 
progression [38, 39]. The inactivation of EMT-TFs 
by the human tumor suppressor micro-RNAs is a new 
epigenetic-targeted therapy for MBC. Consequently, 
several miRNAs, including miR-1 [40], miR-34a [30, 
41, 42], miR-100 [43], miR-125b [44], and miR-142 
[45] have been proposed to inhibit or reduce the EMT 
process during the advanced stage of BC [46]. A number 
of studies have suggested that miR-34a is potentially 
a regulatory microRNA that is usually up-regulated in 
breast, pancreatic, renal and gastric cancer [47–50]. 
Nevertheless, these reports on the interaction between 
miR-34a expression and the inactivation of EMT signaling 
pathway are still limited [46].
Information about regulators and mediators of 
EMT-TFs/miR-34a loops is still murky and unknown. Our 
study seeks to address that miR-34a expression is lower in 
human BC tissues than in normal breast tissues. Studies 
indicated that frequencies of miR-34a expression in the 
BC are controversial [51–53]. The downregulation of 
miR-34a expression in breast could be associated with the 
frequent deletion of chromosome 1p36, TP53 mutations 
and CpG methylation of the miR-34a promoter in these 
tumors [52, 54]. MiR-34a was inactivated by aberrant 
CpG methylation in multiple types of cancer; but breast 
tumors were not investigated yet [52]. A number of studies 
have concluded that knockdown of some EMT-TFs in 
cancer cell lines interacting with miR-34a inhibits cancer 
progression and metastasis [19, 33, 55, 56]. Now, the 
details of how miR-34a physically interacts with EMT-TFs 
and how this interaction inhibits MBC remain unclear. It is 
possible that miR-34a may interact with 3'-UTR of EMT-
TFs by stem-loop structure and change the conformation 
of the binding and landing site of other EMT-activation 
proteins, possibly inhibiting the protein expression of 
EMT and disrupting the post transcriptional modification 
pattern through methylations and ubiquitin-proteasome 
pathway [57]. This hypothesis needs further investigation 
based on epigenetic and structural analyses. Despite this, 
it appears that the reduction of EMT-features and their 
modifications through the interaction between miR-34a 
and EMT-TFs may be a major functional mechanism of 
miR-34a in our present study.
To our knowledge, the correlation between 
downregulation of miR-34a expression and EMT-TFs 
regulations in BC was investigated systematically in 
this study for the first time. Despite some limitations 
in sample size, the current data showed an inverse 
Figure 7: Synergic effects of thymoquinone (TQ) and miR-34a on mRNA (top panel) and protein (bottom panel) level 
expression of EMT-TFs. TQ (5 μM) treatment for 6h for RT-PCR or 12h for Western blot pre-miRNAs (20 ng of each) treatment for 
36 h inhibited the expression of NOTCH1 A., TWIST1 B., and ZEB1 C. in the BT-549 cell line. Results expressed as mean ± SD, and 
independently repeated with three times. qRT-PCR results normalized to 18S or U6 and compared with the untreated cells as a control. In 
western blot β-actin (ACTIN) as an internal control (* P<0.05 and ** P<0.001 versus control group).
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correlation between miR-34a expression and EMT-TFs 
expression in MBC tissues, indicating that miR-34a 
could be a promising and novel noninvasive biomarker 
in BC diagnosing. There is some evidence supporting 
this finding, showing the negative correlations of miR-
34a with the biomarkers of most cancers. Survival time 
and clinicpathological analysis results showed that the 
strongest association of ZEB1 expression is correlated 
with EMT and BC metastasis, raising the question on how 
ZEB1 and NOTCH1 induces EMT signaling activation 
and whether ZEB1’s increased expression in BC cells is 
linked to an altered or disturbed EMT process.
Previous studies indicated that miR-34a significantly 
suppressed proliferation, invasion, and metastasis of 
BC cells, which correlated to the overexpression of 
some EMT-TFs [19, 58, 59]. Some of these results are 
inconsistent with our findings, or not studied in BC. Ahn 
et al. (2012) demonstrated that ZEB1 targeted miR-34a 
as a direct tragedian of miR-34a in human lung cancer 
[60]. However, all these findings indicated that miR-34a 
might have a significant impact on the tumorigenesis of 
human cancer by targeting differential EMT signaling 
pathways other than those in BC. It is likely the initiation 
binding feedback loop of EMT-TFs /miR-34a is different 
depending on the types of cancer cell and physiological 
features. All of this insufficient information could 
contribute to additional inconsistencies and potential 
selection bias. Thus, our data need to be substantiated by 
an appropriate prospective and comprehensive basic study.
Interestingly, this is the first report demonstrating 
that the co-delivery of miR-34a and TQ is able to 
inactivate the downstream of the EMT signaling pathway 
by directly targeting TWIST1 and ZEB1 in vivo. 
Thus, co-delivery of TQ and miR-34a could produce 
synergistic effects on tumor growth and migrations, and 
a nanosystem-based co-delivery of tumor suppressive 
miRNAs and natural compound TQ may be a promising 
combination for therapeutic strategy against MBC by 
Figure 8: Molecular model of BC metastasis suppressed via TQ/miR-34a-initiated signaling pathways. This schematic 
carton shows the major triggering of EMT-inducing signaling pathways, like Wnt proteins (NOTCH), Ras/MAPK kinas, PI3-kinase/
Akt and hypoxia (ROS). Co-delivery of TQ/miR-34a leads to repression of metastatic, cell differentiation, and EMT factures in front of 
inducing of apoptosis and TP53 activations and MET features of BC cell. For more details see manuscript text. TQ, Thymoquinone; miR-
34a, microRNAs-34a; PI3K/AKT, phosphatidylinositol 3-kinase (PI3K)/Akt; ROS, reactive oxygen species; MAPK, Mitogen-Activated 
Protein Kinase; ZEB, zinc-finger E-box-binding; EMT, epithelial to mesenchymal transitions, MET, mesenchymal to epithelial transitions; 
EMT-TFs, EMT-inducing transcription factors.
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down-regulating TWIST1, NOTCH1 and ZEB1 in the 
near future. Previous studies proposed that TQ induces cell 
cycle arrest and triggers apoptosis of tumor cells through 
p38, NF-κB and ERK signaling pathways [11, 35, 61–64]. 
It has been reported that the anti-metastatic effects of TQ 
are likely to be mediated by the stimulation of miRNA 
profiles [35, 65–68]. Targeting miRNA and TQ may 
deliver a new outlook of tumor metastasis suppression by 
targeting EMT-TFs pathways in different cancer cells [35, 
69–71]. It is not yet known whether miRNA’s TQ-targeting 
mechanism and its specifics in controlling EMT could be 
associated with this activity [65, 66, 71]. In our current 
study, we found that EMT-TFs/TQ/miR-34a axis plays 
critical roles in regulating MBC contribution. Based on 
these results, we created a molecular model demonstrating 
the synergistic effect of miR-34a and TQ in MBC cell line 
(Figure 8). Figure 8 shows the transcriptional regulators of 
EMT and a representation of some points of intersection 
at TQ/miR-34a-inducing signaling pathways. These results 
clearly show that TQ/miR-34a is a potential therapeutic 
agent for further development in the management of BC/
MBC. The aforementioned outcomes might help describe 
a possible aim on why EMT-TFs/TQ/miR-34a contributes 
to MBC progression, helping in the identification of a 
novel therapeutic target of MBC progression.
In conclusion, we indicate that the lower level of 
expression of miR-34a could be a promising and novel 
biomarker for MBC. The epigenetic inactivation of the 
EMT-TFs/miR-34a pathway can potentially push the 
equilibrium of these regulations toward EMT, thereby 
contributing to metastasis. MiR-34a alone could serve as 
a potential therapeutic agent for MBC and, combined with 
TQ, they might synergistically enhance the therapeutic 
effects significantly.
MATERIALS AND METHODS
Cell culture and transfections
Two non-metastatic BC cell lines, MCF-7 and 
T-47D, and three MBC cell lines, BT-549, MDA-
MB-231, and MDA-MB-435, were purchased from 
American Type Culture Collection (ATCC, Manassas, VA, 
USA). All these cell lines were cultured in RPMI-1640 
or DMEM supplemented with 10% fetal bovine serum 
(Thermo Fisher Scientific, Waltham, MA, USA) and 1% 
penicillin–streptomycin (Sigma-Aldrich, St Louis, MO, 
USA) [72]. Cell cultures were incubated at 37 °C with 
5% CO2 in a humidified incubator. In this study, TQ was 
purchased from Sigma-Aldrich (St. Louis, MO, USA) and 
suspended in dimethyl sulfoxide (DMSO). In addition, 
different concentrations of TQ were used to treat cancer 
cell lines, while DMSO was used as control. The plasmids 
for miR-34a of miRNA inhibitors (HmiR-AN0440-SN-5), 
precursor miRNA clone in non-viral vectors (HmiR0005-
MR04) and respective negative controls (CmiR-AN0001-
SN, CmiR0005-MR04) (GeneCopoeia, Inc, USA) were 
transfected into 1×105 cells per well in 24 well plates 
(Qiagen, Hilden, Germany).
Plasmids
The wild type DNA fragment containing part 
of the wild type DNA fragment of the 3'-UTR region 
(−1611 to +1617 from the transcriptional initiation site) 
of the TWIST1 gene (NM_000474.3), miRNA 3’ UTR 
TWIST1 target clone in luciferase reporter vector (Cat# 
HmiT018328-MT01) and its miRNA Target clone control 
vector (Cat# CmiT000001-MT01) were purchased from 
GeneCopoeia Co. (GeneCopoeia Inc., MA, USA). The 
plasmids for miR-34a of miRNA inhibitors (HmiR-
AN0440-SN-5), precursor miRNA clone in non-viral 
vectors (HmiR0005-MR04) and respective negative 
controls (CmiR-AN0001-SN, CmiR0005-MR04) were 
purchased from GeneCopoeia, Inc, USA. The wild type 
DNA fragment containing part of the 3'-UTR region 
(−328 to +335 from the transcriptional initiation site) of 
the ZEB1 gene (NM_001174096) were amplified from 
human genomic DNA, and inserted into the pGL3-basic 
(Promega, Madison, WI, USA), an empty pGL3 vector 
used as a control. The mutant DNA sequences of the 
ZEB1, 3'-UTR region was synthesized and inserted into 
pGL3-basic vector. The pGL3-hNOTCH1-Luc reporter 
plasmid was kind gifts from Prof. Benjamin Purow 
(University of Virginia, Charlottesville, VA, USA) [73].
Tissue samples and clinical data
The study was approved by the Ethics Committee 
of the Southwest Medical University according to the 
Helsinki Declaration (1983 Revision) [74, 75, 76]. In total, 
48 fresh or formalin-fixed, paraffin-embedded MBC cases 
surgical biopsy specimens were obtained from affiliated 
Hospital of Southwest Medical University. All cases 
were diagnosed and confirmed by two oncologists and 
pathologist according to the World Health Organization 
(WHO) guidelines and the pTNM Union for International 
Cancer Control (UICC) pathological staging criteria. All 
patients signed consent and completed the questionnaire. 
The demographic and histopathologic variables of the all 
subjects such as medical, reproductive, family history, 
body mass index, tumor size, node status, disease stage, 
treatment and survival was obtained correctly according 
the interviewer-administered questionnaire. Based on the 
inclusion/exclusion criteria, the matched tumor tissues 
and non-tumor tissues samples comprised of 33 breast 
tumors, as well as normal breast tissues (n = 15) from 
epileptic resections. The tissues were immediately frozen 
in liquid nitrogen and stored at -80 °C until future RNA 
and protein extraction [74]. Most demographic and clinical 
characteristics of the subjects were compared and shown 
in Supplementary Table 1.
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Quantitative real-time PCR
To quantify the expression of mRNA, qRT-PCR was 
performed according to standard protocols as previously 
described [35, 77]. Testing for hsa-miR-34a (Cat# 
4427975) was purchased from ABI. 18S or U6 snRNA 
from ABI (Cat# 4427975) was set as internal control. 
Primers were listed in Supplementary Table 2.
Western blot
Total cell lysate of BC cell lines and frozen biopsies 
of human breast tissues were corrected by ice-cold RIPA 
lysis buffer (Roche, Diagnostics, Mannheim, Germany). 
A quantity of approximately 30 μg of whole cell lysates 
per lane were separated using SDS polyacrylamide 
gels electrophoresis (SDS-PAGE) and transferred on to 
Immobilon PVDF membranes (Millipore, Corporation, 
Billerica, MA, USA) and probed with antibodies listed in 
the Supplementary Table 3.
Cell growth, migration and invasion assay
The real time analysis of cell migration, growth 
index and invasion were performed by using a real time 
cell analyzer (xCELLigence RTCA DP, Roche, Germany), 
as previously described in detail [35, 77].
Luciferase reporter assay
The assays were performed according to standard 
protocols as previously described [35, 76]. In brief, assays 
were carried out by transfection of 10 ng of each reporter 
constructs in BT-549 cells that were with 0, 10, 30, and 
90 ng miR-34a precursors respectively (Thermo Fisher 
Scientific) in 24-well plates. Dual-luciferase activity, 
expressed as relative light units (RLU), was measured 
using a luciferase kit (Promega, Madison, WI, USA).
Bioinformatics
Prediction potential targets of hsa-miR-34a in the 3’-
UTR of EMT-TFs was found by using the bioinformatics 
analysis based on the target prediction tools TargetScan 
(http://www.targetscan.org; release 5.1), PicTar (http://
pictar.mdc-berlin.de) and miRanda (http://www.microrna.
org) and miRWalk (http://www.ma.uni-heidelberg). The 
online Kaplan-Meier data set tool was used to analyze the 
association between survival time and EMT-TFs (http://
www.kmplot.com/analysis/) [34].
Statistics analysis
All statistical analyses were performed using SPSS 
software version 21.0 (SPSS Inc., Chicago, IL, USA) with 
unpaired Student’s t-test or otherwise stated. All graphs 
were produced by GraphPad Prism 5.0 for windows 
software (GraphPad Software Inc., La Jolla, CA, USA).
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